8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Mar 11, 2026·SEC
SELLAS Life Sciences Group, Inc.(SLS)Earnings, Financials & Key Ratios
SLS•NASDAQ
Price updated Jun 19, 2026
AboutSELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$28M
- Net Income-$27M+13.0%
- EPS (Diluted)-0.25+50.0%
- ROE-66.88%+98.4%
SLS Key Insights
SELLAS Life Sciences Group, Inc. (SLS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 97 (top 3%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 78.2% in last year
- ✗Expensive at 12.4x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SLS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLS Price & Volume
SELLAS Life Sciences Group, Inc. (SLS) stock price & volume — 10-year historical chart
Loading chart...
SLS Growth Metrics
SELLAS Life Sciences Group, Inc. (SLS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.59%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM40.28%
Return on Capital
10 Years-421.08%
5 Years-773.26%
3 Years-1344.57%
Last Year-69.6%
SLS Recent Earnings
SELLAS Life Sciences Group, Inc. (SLS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.05+16.7%
$0.06
Rev
—
—
Q2 2026
Mar 19, 2026Metric
Actual
Est
EPS
$0.05+21.0%
$0.06
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.06+5.3%
$0.06
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.07+16.0%
$0.08
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.05vs $0.06+16.7% | — |
| Q2 2026 | Mar 19, 2026 | $0.05vs $0.06+21.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.06vs $0.06+5.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.07vs $0.08+16.0% | — |
Based on last 12 quarters of dataView full earnings history →
SLS Peer Comparison
SELLAS Life Sciences Group, Inc. (SLS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 CLDX | 2.16B | 32.43 | -8.32 | -78.63% | -345.96% | -50.72% | 0.00 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% | |||
 IOVA | 1.4B | 3.91 | -3.59 | 60.6% | -123.9% | -50.17% | 0.07 |
Compare SLS vs Peers
SELLAS Life Sciences Group, Inc. (SLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLS Income Statement
SELLAS Life Sciences Group, Inc. (SLS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 1.9M | 7.6M | 1M | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | 300% | -86.84% | -100% | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 200K | 100K | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | 2.63% | 10% | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 1.9M▲ 0% | 7.4M▲ 289.5% | 900K▼ 87.8% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | 100% | 97.37% | 90% | - | - | - | - |
Gross Profit Growth % | 100% | - | - | - | 289.47% | -87.84% | -100% | - | - | - |
Operating Expenses | 21.16M | 31.59M | 20.04M | 18.88M | 32.69M | 42.85M | 37.87M | 31.51M | 28.27M | 31.46M |
OpEx % of Revenue | - | - | - | 993.79% | 430.18% | 4285% | - | - | - | - |
Selling, General & Admin | 15.09M | 12.77M | 9.92M | 9.6M | 11.32M | 12.58M | 13.86M | 12.42M | 12.25M | 13.52M |
SG&A % of Revenue | - | - | - | 505.26% | 148.95% | 1258.2% | - | - | - | - |
Research & Development | 6.07M | 18.32M | 10.12M | 9.28M | 21.37M | 30.27M | 24.01M | 19.1M | 16.02M | 17.95M |
R&D % of Revenue | - | - | - | 488.53% | 281.24% | 3026.8% | - | - | - | - |
Other Operating Expenses | 0 | -3.03M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -15.71M▲ 0% | -31.59M▼ 101.0% | -20.04M▲ 36.6% | -16.98M▲ 15.3% | -25.29M▼ 48.9% | -41.95M▼ 65.8% | -37.87M▲ 9.7% | -31.51M▲ 16.8% | -28.27M▲ 10.3% | -31.46M▲ 0% |
Operating Margin % | - | - | - | -893.79% | -332.82% | -4195% | - | - | - | - |
Operating Income Growth % | 1.71% | -101.02% | 36.56% | 15.26% | -48.95% | -65.85% | 9.73% | 16.78% | 10.28% | - |
EBITDA | -15.71M | -9.55M | -2.83M | -16.61M | -24.02M | -41.49M | 0 | 0 | -28.27M | -24.11M |
EBITDA Margin % | - | - | - | -873.95% | -316.07% | -4149.3% | - | - | - | - |
EBITDA Growth % | 1.71% | 39.21% | 70.34% | -486.13% | -44.66% | -72.74% | 100% | - | - | 35.84% |
D&A (Non-Cash Add-back) | 3K | 22.04M | 17.21M | 377K | 1.27M | 457K | 37.87M | 31.51M | 0 | 7.08M |
EBIT | -23.04M | -28.78M | -17.21M | -16.77M | -19.59M | -31.95M | -37.34M | -30.88M | -28.27M | -30.9M |
Net Interest Income | 0 | 0 | 0 | 26K | 6K | 317K | 525K | 632K | 1.41M | 2.01M |
Interest Income | 0 | 0 | 118K | 26K | 6K | 317K | 525K | 632K | 1.41M | 2.01M |
Interest Expense | 462K | 266K | 118K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | -7.79M | 2.54M | 668K | 208K | 4.36M | 649K | 529K | 632K | 1.41M | 2.01M |
Pretax Income | -23.5M▲ 0% | -29.05M▼ 23.6% | -19.37M▲ 33.3% | -16.77M▲ 13.4% | -20.94M▼ 24.8% | -41.3M▼ 97.3% | -37.34M▲ 9.6% | -30.88M▲ 17.3% | -26.86M▲ 13.0% | -29.46M▲ 0% |
Pretax Margin % | - | - | - | -882.84% | -275.47% | -4130.1% | - | - | - | - |
Income Tax | 253K | -1.38M | -81K | -17K | -237K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -1.08% | 4.74% | 0.42% | 0.1% | 1.13% | 0% | 0% | 0% | 0% | 0% |
Net Income | -23.75M▲ 0% | -27.67M▼ 16.5% | -19.29M▲ 30.3% | -16.76M▲ 13.1% | -20.7M▼ 23.5% | -41.3M▼ 99.5% | -37.34M▲ 9.6% | -30.88M▲ 17.3% | -26.86M▲ 13.0% | -29.46M▲ 0% |
Net Margin % | - | - | - | -881.95% | -272.36% | -4130.1% | - | - | - | - |
Net Income Growth % | -0.87% | -16.49% | 30.28% | 13.14% | -23.52% | -99.53% | 9.59% | 17.3% | 13.01% | -8.59% |
Net Income (Continuing) | -23.75M | -27.67M | -19.29M | -16.76M | -20.7M | -41.3M | -37.34M | -30.88M | -26.86M | -29.46M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -521.91▲ 0% | -157.72▲ 69.8% | -10.92▲ 93.1% | -2.11▲ 80.7% | -1.34▲ 36.5% | -2.13▼ 59.0% | -1.34▲ 37.1% | -0.50▲ 62.7% | -0.25▲ 50.0% | -0.17▲ 0% |
EPS Growth % | 44.07% | 69.78% | 93.08% | 80.68% | 36.49% | -58.96% | 37.09% | 62.69% | 50% | 40.28% |
EPS (Basic) | -521.91 | -157.72 | -10.92 | -2.11 | -1.34 | -2.13 | -1.34 | -0.50 | -0.25 | - |
Diluted Shares Outstanding | 46.81K | 261.54K | 2.56M | 7.98M | 15.48M | 19.4M | 27.78M | 61.2M | 109.05M | 172.48M |
Basic Shares Outstanding | 45K | 175K | 1.77M | 7.94M | 15.48M | 19.39M | 27.78M | 61.2M | 109.05M | 172.48M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SLS Balance Sheet
SELLAS Life Sciences Group, Inc. (SLS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 13.09M | 5.84M | 8.24M | 36.92M | 23.04M | 17.76M | 3.17M | 16.33M | 75.21M | 111.17M |
Cash & Short-Term Investments | 2.32M | 5.34M | 7.28M | 35.3M | 21.45M | 17.13M | 2.53M | 13.89M | 71.89M | 107.2M |
Cash Only | 2.32M | 5.34M | 7.28M | 35.3M | 21.45M | 17.13M | 2.53M | 13.89M | 71.89M | 107.2M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 308K | 1.13M | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | 216.69 | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 10.43M | 291K | 184K | 130K | 27K | 330K | 100K | 100K | 3.32M | 3.97M |
Total Non-Current Assets | 20.44M | 11.08M | 8.37M | 9.12M | 3.38M | 3.19M | 3.05M | 3.31M | 3.13M | 3.01M |
Property, Plant & Equipment | 0 | 0 | 217K | 896K | 723K | 874K | 858K | 925K | 963K | 839K |
Fixed Asset Turnover | - | - | - | 2.12x | 10.51x | 1.14x | - | - | - | 0.00x |
Goodwill | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M |
Intangible Assets | 17.6M | 8.5M | 5.7M | 5.7M | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | -184K | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 925K | -765K | 536K | 614K | 594K | 399K | 275K | 466K | 257K | 255K |
Total Assets | 33.53M▲ 0% | 16.91M▼ 49.5% | 16.61M▼ 1.8% | 46.05M▲ 177.3% | 26.43M▼ 42.6% | 20.94M▼ 20.8% | 6.22M▼ 70.3% | 19.43M▲ 212.5% | 78.34M▲ 303.2% | 114.18M▲ 0% |
Asset Turnover | - | - | - | 0.04x | 0.29x | 0.05x | - | - | - | 0.00x |
Asset Growth % | -49.06% | -49.55% | -1.81% | 177.25% | -42.61% | -20.75% | -70.31% | 212.46% | 303.18% | 737.99% |
Total Current Liabilities | 24.57M | 5.97M | 5.29M | 12.34M | 4.98M | 15.52M | 13.73M | 9.51M | 7.02M | 6.46M |
Accounts Payable | 11.69M | 3.75M | 3.9M | 4.66M | 2.14M | 3.36M | 5.64M | 3.5M | 2.95M | 3.63M |
Days Payables Outstanding | - | - | - | - | 3.91K | 12.25K | - | - | - | - |
Short-Term Debt | 8.38M | 0 | 0 | 0 | 198K | 0 | 0 | 0 | 544K | 562K |
Deferred Revenue (Current) | 4.31M | 0 | 0 | 5.6M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.49M | 8K | 606K | 1.01M | 1.65M | 5.5M | 1.53M | 1.82M | 3.52M | 2.26M |
Current Ratio | 0.53x | 0.98x | 1.56x | 2.99x | 4.63x | 1.14x | 0.23x | 1.72x | 10.72x | 17.22x |
Quick Ratio | 0.53x | 0.98x | 1.56x | 2.99x | 4.63x | 1.14x | 0.23x | 1.72x | 10.72x | 17.22x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 6.89M | 5.7M | 5.23M | 5.75M | 1.1M | 577K | 460K | 457K | 457K | 309K |
Long-Term Debt | 2.61M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 309K |
Capital Lease Obligations | 0 | 0 | 0 | 825K | 610K | 573K | 460K | 457K | 457K | 157K |
Deferred Tax Liabilities | 1.67M | 357K | 262K | 239K | 152K | 184K | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2.6M | 5.34M | 4.96M | 4.69M | 336K | 4K | 0 | 0 | 0 | 0 |
Total Liabilities | 31.46M | 11.67M | 10.52M | 18.09M | 6.08M | 16.09M | 14.2M | 9.97M | 7.47M | 6.76M |
Total Debt | 10.99M | 0 | 217K | 991K | 808K | 945K | 906K | 1M | 1M | 871K |
Net Debt | 8.67M | -5.34M | -7.06M | -34.31M | -20.65M | -16.18M | -1.62M | -12.88M | -70.89M | -106.33M |
Debt / Equity | 5.31x | - | 0.04x | 0.04x | 0.04x | 0.19x | - | 0.11x | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 4.41x |
Interest Coverage | -49.87x | -108.20x | -145.83x | - | - | - | - | - | - | - |
Total Equity | 2.07M▲ 0% | 5.25M▲ 153.4% | 6.09M▲ 16.2% | 27.96M▲ 358.9% | 20.35M▼ 27.2% | 4.85M▼ 76.2% | -7.98M▼ 264.4% | 9.46M▲ 218.7% | 70.87M▲ 648.8% | 107.41M▲ 0% |
Equity Growth % | -92.78% | 153.38% | 16.17% | 358.9% | -27.23% | -76.16% | -264.42% | 218.67% | 648.77% | 1920.51% |
Book Value per Share | 44.22 | 20.05 | 2.38 | 3.51 | 1.31 | 0.25 | -0.29 | 0.15 | 0.65 | 0.62 |
Total Shareholders' Equity | 2.07M | 5.25M | 6.09M | 27.96M | 20.35M | 4.85M | -7.98M | 9.46M | 70.87M | 107.41M |
Common Stock | 1K | 2K | 1K | 1K | 2K | 2K | 3K | 7K | 15K | 18K |
Retained Earnings | -54.19M | -81.86M | -101.15M | -117.9M | -138.6M | -179.9M | -217.24M | -248.13M | -274.99M | -283.39M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLS Cash Flow Statement
SELLAS Life Sciences Group, Inc. (SLS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -10.99M | -30.42M | -17.64M | -10.42M | -26.02M | -23.81M | -31.41M | -35.4M | -28.39M | -28.16M |
Operating CF Margin % | - | - | - | -548.26% | -342.38% | -2380.9% | - | - | - | - |
Operating CF Growth % | 75.53% | -176.84% | 42.01% | 40.96% | -149.79% | 8.5% | -31.92% | -12.71% | 19.81% | 67.42% |
Net Income | -23.75M | -27.67M | -19.29M | -16.76M | -20.7M | -41.3M | -37.34M | -30.88M | -26.86M | -29.46M |
Depreciation & Amortization | 0 | 3.76M | 1.7M | 282K | 5.68M | 457K | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 3.17M | 395K | 573K | 578K | 1.01M | 1.73M | 1.39M | 1.56M | 1.96M | 1.45M |
Deferred Taxes | 0 | -1.32M | -95K | -23K | -239K | -457K | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 3.53M | 4.42M | 586K | -87K | -4.16M | 10.13M | 1.2M | 561K | 597K | 1.4M |
Working Capital Changes | 6.07M | -10.01M | -1.11M | 5.59M | -7.62M | 5.64M | 3.35M | -6.65M | -4.08M | -1.56M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 8.37M | -7.94M | 12K | -836K | -2.51M | 1.21M | 2.3M | -2.14M | -535K | -127K |
Cash from Investing | 1.81M | 0 | 0 | 0 | 0 | -4.5M | -5.5M | 0 | 0 | 0 |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | -4.5M | -5.5M | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | 450% | - | - | - | - |
Acquisitions | 1.81M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 5.53M | 23.12M | 19.57M | 38.44M | 12.07M | 24.08M | 22.32M | 46.76M | 86.3M | 106.86M |
Debt Issued (Net) | -473K | -7.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 6.01M | 31.21M | 15.97M | 29.6M | 9.01M | 23.99M | 22.23M | 46.16M | 86.82M | 107.39M |
Dividends Paid | -675K | -487K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 3.6M | 8.84M | 3.07M | 85K | 90K | 594K | -527K | -527K |
Net Change in Cash | -3.64M▲ 0% | -7.3M▼ 100.4% | 1.93M▲ 126.4% | 28.02M▲ 1355.1% | -13.95M▼ 149.8% | -4.23M▲ 69.7% | -14.6M▼ 245.0% | 11.36M▲ 177.8% | 57.91M▲ 409.9% | 78.7M▲ 0% |
Free Cash Flow | -10.99M▲ 0% | -30.42M▼ 176.8% | -17.64M▲ 42.0% | -10.42M▲ 41.0% | -26.02M▼ 149.8% | -28.31M▼ 8.8% | -36.91M▼ 30.4% | -35.4M▲ 4.1% | -28.39M▲ 19.8% | -28.16M▲ 0% |
FCF Margin % | - | - | - | -548.26% | -342.38% | -2830.9% | - | - | - | - |
FCF Growth % | 75.54% | -176.84% | 42.01% | 40.96% | -149.79% | -8.79% | -30.38% | 4.09% | 19.81% | 16.45% |
FCF per Share | -234.77 | -116.32 | -6.90 | -1.31 | -1.68 | -1.46 | -1.33 | -0.58 | -0.26 | -0.16 |
FCF Conversion (FCF/Net Income) | 0.46x | 1.10x | 0.91x | 0.62x | 1.26x | 0.58x | 0.84x | 1.15x | 1.06x | 0.96x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLS Key Ratios
SELLAS Life Sciences Group, Inc. (SLS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -154.61% | -756.53% | -340.31% | -98.41% | -85.7% | -327.81% | - | -4147.88% | -66.88% | -47.12% |
Return on Invested Capital (ROIC) | -62.51% | -445.04% | - | - | - | - | - | - | - | -2114.92% |
Gross Margin | - | - | - | 100% | 97.37% | 90% | - | - | - | - |
Net Margin | - | - | - | -881.95% | -272.36% | -4130.1% | - | - | - | - |
Debt / Equity | 5.31x | - | 0.04x | 0.04x | 0.04x | 0.19x | - | 0.11x | 0.01x | 0.01x |
Interest Coverage | -49.87x | -108.20x | -145.83x | - | - | - | - | - | - | - |
FCF Conversion | 0.46x | 1.10x | 0.91x | 0.62x | 1.26x | 0.58x | 0.84x | 1.15x | 1.06x | 0.96x |
Revenue Growth | - | - | - | - | 300% | -86.84% | -100% | - | - | - |
Related:SLS Dividend History·SLS Revenue History·SLS Price History·SLS P/E History·SLS Financial Ratios·SLS Institutional Holders
SLS SEC Filings & Documents
SELLAS Life Sciences Group, Inc. (SLS) SEC filings — annual & quarterly reports (10-K, 10-Q)
SLS Frequently Asked Questions
SELLAS Life Sciences Group, Inc. (SLS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
SELLAS Life Sciences Group, Inc. (SLS) grew revenue by 0.0% over the past year. Growth has been modest.
SELLAS Life Sciences Group, Inc. (SLS) reported a net loss of $29.5M for fiscal year 2025.
Dividend & Returns
SELLAS Life Sciences Group, Inc. (SLS) has a return on equity (ROE) of -66.9%. Negative ROE indicates the company is unprofitable.
SELLAS Life Sciences Group, Inc. (SLS) had negative free cash flow of $28.2M in fiscal year 2025, likely due to heavy capital investments.